Pulse Biosciences, Inc.

NasdaqCM PLSE

Pulse Biosciences, Inc. Receivables for the quarter ending September 30, 2024

Pulse Biosciences, Inc. Receivables is NA for the quarter ending September 30, 2024. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Pulse Biosciences, Inc. Receivables for the quarter ending September 30, 2023 was USD 0.00, a -100.00% change year over year.
Pulse Biosciences, Inc. Receivables for the quarter ending September 30, 2022 was USD 5.00 K, a -93.06% change year over year.
Pulse Biosciences, Inc. Receivables for the quarter ending September 30, 2021 was USD 72.00 K, a 0.00% change year over year.
Pulse Biosciences, Inc. Receivables for the quarter ending September 30, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

NasdaqCM: PLSE

Pulse Biosciences, Inc.

CEO	Mr. Robert W. Duggan
IPO Date	May 18, 2016
Location	United States
Headquarters	3957 Point Eden Way
Employees	56
Sector	Health Care
Industries Biotechnology Energy Storage & Batteries Pharmaceuticals

Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Key trends

Past 5 years